NCT02472938View on ClinicalTrials.gov

Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2015

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2020

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

dimethyl fumarate

dimethyl fumarate 120 mg capsules

OTHER

Placebo

Placebo for BG00012

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
collaborator

GB Pharma Services & Consulting s.r.l.

INDUSTRY

lead

Biogen

INDUSTRY